Novo will harness Anthropic’s AI assistant Claude to accelerate research and development (R&D) activities, as the drugmaker looks to regain its once-dominant position at the fro ...

Sling is racing to market the first oral IGF-1R blocker, which would likely provide competition to Amgen’s Tepezza.

The HHS appoints these leadership positions as it looks to “reform” the FDA, which has recently faced a high turnover in leadership.

Definium Therapeutics plans to submit an NDA for LSD-based psychedelic, DT120 in generalised anxiety disorder (GAD) during H1 2027.

Share prices tumbled last week after a key asset from Novartis’ $12bn Avidity deal fumbled in a Phase III trial.

The FDA has granted accelerated approval to AstraZeneca's Etcamah (camizestrant), used with a CDK 4/6 inhibitor, for breast cancer.

ABEC is to open a new manufacturing facility in Wilson, North Carolina, US, expanding its network for biopharmaceutical process equipment.

A survey of 175 pharma executives highlights an increasing reluctance to launch in lower-value markets, alongside a heightened focus on RWE.

Cell and gene therapies are fuelling new possibilities for rare diseases, turning a field defined by unmet need into one of the industry’s most dynamic areas of innovation.

As regulatory enforcement surges, life science manufacturers must shift away from paper-based systems to ensure compliance.

At ERS 2026, investigators reported their findings from their review of the Oxford Asthma Attack Risk Scale Meta-Analysis (ORACLE2).

Though yet to be finalised, the initial recommendation would mean the injectable PrEP would not be covered on the NHS.